Stock GLENMARK GLENMARK PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Glenmark Pharmaceuticals Limited

Equities

GLENMARK

INE935A01035

Delayed NSE India S.E.
Other stock markets
 01:00:39 2024-05-03 am EDT 		5-day change 1st Jan Change
1,062 INR +0.13% Intraday chart for Glenmark Pharmaceuticals Limited +2.56% +24.25%
Apr. 29 Glenmark Pharmaceuticals Gets US FDA's Final Approval for Generic Pain Relief Medicines MT
Apr. 25 Glenmark Lifesciences' Net Profit Slides in Fiscal Q4 MT

Evolution of the average Target Price on Glenmark Pharmaceuticals Limited

Price target over the last 5 years

History of analyst recommendation changes

9895bd4924d12.jCZrTNvQ4XNIr2OwaSJaDd9iBoLPZ09VkTPV2Lc1nqY.2mpeD4HppxcjnwqBL1QyTpcFYLuZHjw0yXCPj-Bm9PniaS8C6-K-BRmcJg~4f70b661d3923dddcdc544d37a45ce29

Analyst Recommendations on Glenmark Pharmaceuticals Limited

Nomura Adjusts Glenmark Pharmaceuticals’ Price Target to INR909 From INR841, Keeps at Neutral MT
Indian shares set to open higher ahead of national budget RE
Nomura Downgrades Glenmark Pharmaceuticals to Neutral From Buy, Adjusts Price Target to INR841 From INR633 MT
INDIA STOCKS-India's Sensex logs worst week in 15 months on rate worries RE
Indian Equities Close Flat, Weighed Down by Worries Over US Rate Hikes, Weak Chinese Economy MT
Nomura Adjusts Glenmark Pharmaceuticals' Price Target to INR633 From INR580, Keeps at Buy MT
Nomura Adjusts Glenmark Pharmaceuticals' Price Target to 580 Indian Rupees From 757 Rupees, Keeps at Buy MT
Indian shares may open higher, tracking Asia RE
Crisil Keeps AA- Rating on Glenmark Pharmaceuticals; Raises Outlook to Positive MT
S&P Raises Glenmark Pharmaceuticals' Rating to BB on Plan to Cut Debt MT
GLENMARK PHARMACEUTICALS : Nomura Adjusts Glenmark Pharmaceuticals' Price Target to 757 Indian Rupees From 762 Indian Rupees, Keeps at Buy MT
GLENMARK PHARMACEUTICALS : Nomura Adjusts Glenmark Pharmaceuticals' Price Target to 762 Indian Rupees From 727 Indian Rupees, Keeps at Buy MT
Glenmark Pharmaceuticals : S&P Global Maintains Glenmark Pharmaceuticals' BB- Issuer Credit Rating; Outlook Stable MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
1,060 INR
Average target price
962.8 INR
Spread / Average Target
-9.21%
High Price Target
1,266 INR
Spread / Highest target
+19.38%
Low Price Target
570 INR
Spread / Lowest Target
-46.25%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Glenmark Pharmaceuticals Limited

Nomura

Ratings for Glenmark Pharmaceuticals Limited

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GLENMARK Stock
  4. Consensus Glenmark Pharmaceuticals Limited